Lineage Cell Therapeutics (LCTX) Receivables - Net (2011 - 2026)

Lineage Cell Therapeutics' Receivables - Net history runs 16 years deep, the most recent figure standing at $806000.0 for Q1 2026.

• In Q1 2026, Receivables - Net rose 278.4% year-over-year to $806000.0; the TTM figure through Mar 2026 stood at $806000.0 (up 278.4% YoY), while the FY2025 annual figure was $891000.0, up 39.66% from the prior year.
• Receivables - Net for Q1 2026 stood at $806000.0, down from $891000.0 in the prior quarter.
• The five-year high for Receivables - Net was $891000.0 in Q4 2025, with the low at $77000.0 in Q1 2024.
• The 5-year median for Receivables - Net is $405000.0 (2024), against an average of $411411.8.
• The sharpest annual moves came in 2022 and 2026: Receivables - Net tumbled 99.41% in 2022, then surged 278.4% in 2026.
• Lineage Cell Therapeutics' Receivables - Net stood at $300000.0 in 2022, then soared by 148.33% to $745000.0 in 2023, then retreated by 14.36% to $638000.0 in 2024, then soared by 39.66% to $891000.0 in 2025, then declined by 9.54% to $806000.0 in 2026.
• Business Quant data shows LCTX's Receivables - Net at $806000.0 in Q1 2026, $891000.0 in Q4 2025, and $127000.0 in Q3 2025.